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RESEARCH ARTICLE
Engineering and characterization of human 
β-defensin-3 and its analogues and microcin 
J25 peptides against Mannheimia haemolytica 
and bovine neutrophils
Harpreet Dhingra1, Kamaljit Kaur2 and Baljit Singh1*  
Abstract 
Mannheimia haemolytica-induced bovine respiratory disease causes loss of millions of dollars to Canadian cattle 
industry. Current antimicrobials are proving to be ineffective and leave residues in meat. Antimicrobial peptides 
(AMPs) may be effective against M. haemolytica while minimizing the risk of drug residues. Cationic AMPs can kill 
bacteria through interactions with the anionic bacterial membrane. Human β-Defensin 3 (HBD3) and microcin J25 
(MccJ25) are AMPs with potent activity against many Gram-negative bacteria. We tested the microbicidal activity 
of wild-type HBD3, three HBD3 peptide analogues (28 amino acid, 20AA, and 10AA) derived from the sequence of 
natural HBD3, and MccJ25 in vitro against M. haemolytica. Three C-terminal analogues of HBD3 with all cysteines 
replaced with valines were manually synthesized using solid phase peptide synthesis. Since AMPs can act as chemoat-
tractant we tested the chemotactic effect of HBD3, 28AA, 20AA, and 10AA peptides on bovine neutrophils in Boyden 
chamber. Minimum bactericidal concentration (MBC) assay showed that M. haemolytica was intermediately sensitive 
to HBD3, 28AA and 20AA analogues with an MBC of 50 µg/mL. The 10AA analogue had MBC 6.3 µg/mL which is likely 
a result of lower final inoculum size. MccJ25 didn’t have significant bactericidal effect below an MBC < 100 µg/mL. 
Bovine neutrophils showed chemotaxis towards HBD3 and 20AA peptides (P < 0.05) but not towards 28AA analogue. 
Co-incubation of neutrophils with any of the peptides did not affect their chemotaxis towards N-formyl-l-methionyl-
l-leucyl-phenylalanine (fMLP). The data show that these peptides are effective against M. haemolytica and are chemot-
actic for neutrophils in vitro.
Keywords: HBD3, Microcin J25, Cationic anti-microbial peptides, Solid phase peptide synthesis (SPPS), Bovine 
neutrophils, Chemotaxis
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Cattle industry is a major contributor to global economy 
and is expected to play a critical role in meeting nutri-
tional needs of expanding middle classes in emerging 
economies such as China and India. For example, Canada 
has nearly 83 000 cattle farms and ranches and this sec-
tor contributes upwards of $20 billion a year to Canadian 
economy [1]. The beef and dairy cattle industry suffer 
significant economic losses due to Mannheimia haemo-
lytica-induced Bovine respiratory disease (BRD) [2]. M. 
haemolytica, a Gram-negative coccobacillus that causes 
pneumonia in cattle, resides in the nasopharynx of cat-
tle in a commensal relationship, but stress and viral infec-
tions compromise host defenses giving M. haemolytica 
an opportunity to invade lungs and cause infection [3]. 
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A variety of vaccines and antibiotics against M. haemo-
lytica are available but control and prevention are still a 
problem and due to which approximately $1 billion per 
year are lost by the US cattle industry [2–6] with simi-
lar relative losses in other countries such as Australia and 
Canada [7]. There is a growing evidence of development 
of resistance in M. haemolytica against commonly used 
antimicrobials and a call to take quick steps to develop 
new and effect anti-microbials to combat this pathogen 
[8, 9]. Problems such as antibiotic resistance, antibiotic 
residue in meat and an inadequacy of vaccines push for 
the search of alternative treatments.
In this context, antimicrobial peptides (AMPs) have 
received significant attention as alternatives to antibiotics 
[10, 11]. Human β-Defensin 3 (HBD3) has been isolated 
from airways surface fluid from patients with psoriasis, 
suggesting it may play a role in fighting local infection 
[12]. Recent work by the Caswell laboratory has shown 
that treatment with naturally expressed Tracheal Antimi-
crobial Peptide, a defensin, neither killed M. haemolytica 
nor prevented the development of lung disease [13, 14]. 
Coupled with the fact that M. haemolytica, in normal 
condition, is prevented from entering into the lungs by 
the host’s innate defense mechanism which includes the 
bovine defensins [3], it was thought that HBD3 peptide 
might be effective in M. haemolytica-induced pneu-
monia. Microcins are another class of AMPs which are 
produced by bacteria such as E. coli. Microcins inhibit 
the growth of many pathogenic Gram-negative bacteria 
with Minimum inhibitory concentration (MIC), in the 
nanomolar range [11, 15–20]. Specifically, MicrocinJ25 
(MccJ25) is a peptide comprised of 21 amino acids and 
is active against many Gram-negative bacteria such as 
Escherichia coli and Salmonella [21]. Mccj25 is stable 
in the presence of many proteolytic enzymes because of 
its unique lasso like structure [11]. Considering the eco-
nomic impact of M. haemolytica infections in cattle and 
lack of effective anti-microbial peptides to replace anti-
biotics, we hypothesize that HBD3 and MccJ25 might 
prove as potential candidates for application in the treat-
ment of BRD. The objective of the current study was to 
design, synthesize, purify and evaluate the antimicrobial 
activity of HBD3, its analogues, and recombinant MccJ25 
against M. haemolytica.
Materials and methods
Expression and purification of microcin J25
Wild-type Microcin J25 (MccJ25) was used in this study 
as formation of the lasso ring is not possible synthetically. 
The peptide was expressed using MccJ25 biosynthetic 
gene cluster carrying plasmid pTUC202 (a gift from Rut-
gers University USA) in competent E. coli MC4100 cells 
[25]. It was grown in 2L M9 minimal media for 18 h at 
37 °C. The culture supernatant was obtained by centrifu-
gation at 4000  g for 15  min, and then subjected to two 
successive purification steps. First, it was applied on the 
flex column filled with XAD16 resin (Sigma-Aldrich, 
St. Louis, USA). Two successive elution steps were per-
formed with (30:70, v/v) and (80:20, v/v) methanol/water 
mixtures. MccJ25 is eluted in the (80:20, v/v) methanol/
water mixture. MccJ25 was purified using reversed-phase 
(RP) HPLC (Varian Prostar 210, SpectraLab Scientific 
Inc. Markham, Canada). The purity of the peptides was 
confirmed by MALDI-TOF mass spectrometry.
Synthesis and purification of HBD3 analogues
HBD3 fragments were synthesized manually on 2-chlo-
rotrityl chloride resin (0.2 mmol, 1 mmol/g) following the 
standard Fmoc solid phase peptide synthesis (SPPS) [22]. 
The first amino acid was coupled using DIPEA for 5  h. 
Further amino acids were coupled at twofold excess using 
HCTU/HOBT/NMM as activating mixture in DMF. 
Amino acid coupling was performed for 3 h at room tem-
perature to ensure the completeness of the reaction, fol-
lowed by Fmoc group deprotection using piperidine in 
DMF. These two reactions were repeated until assembly 
of the peptide was complete. A Kaiser test was performed 
after coupling of each amino acid. After completion of 
the synthesis, peptides were cleaved from the resin and 
all protecting groups were removed using cleavage mix-
ture at room temperature. Cleaved peptide was concen-
trated by rotary evaporation. Cold ether was added to 
precipitate the peptide and crude peptide was isolated 
after centrifugation. Crude peptides were dissolved in 
water and purified using RP-HPLC (Varian Prostar 201). 
The purity of the peptides was confirmed by RP-HPLC 
and MALDI-TOF mass spectrometry.
Antimicrobial activity testing of peptides
Wild-type HBD3, its analogues, and MccJ25 were tested 
against M. haemolytica-A1 using optical density method 
and colony count assay. Briefly, an aliquot (5  µL) from 
bacteria suspension stored at −80  °C was put in 5  mL 
BHI broth at 37 °C for 18 h. An aliquot (10 µL) from this 
overnight culture was added to fresh BHI broth and incu-
bated at 37 °C for a further 5 h to obtain mid-log phase 
bacteria. The culture was then centrifuged for 10  min 
at 800 g at 4  °C. The supernatant was discarded and the 
bacterial pellet was resuspended in cold, sterile sodium 
phosphate buffer (SPB) and washed again at 800g for 
10 min at 4 °C. The pellet was resuspended in 5 mL SPB. 
To calculate the number of CFU/mL in the 5 h culture, 
six successive tenfold dilutions were made. From the last 
dilution 100  µL was plated in duplicate on petri dishes 
containing BHI agar and incubated for 24 h. After 24 h 
the colonies were counted in the two petri dishes and 
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then averaged. Total number of colonies was the average 
number of colonies multiplied by the dilution factor.
All assays were carried out in sterile 96-well polypro-
pylene flat-bottomed plates using a broth microdilution 
method. Two-fold serial dilutions of peptide were made 
in SPB, and 50 µL of each concentration of peptide was 
added to the wells of the assay plate. Fifty  µL (25  000 
cells) of the bacterial suspension adjusted to 5 ×  105 cfu/
mL in incubation media was prepared by adding 200 µL 
of BHI broth in 6.8 mL SPB and added to each well. Posi-
tive control wells contained 50  µL of the bacteria with 
50 µL of 64 µg/mL ampicillin and negative control wells 
contained 50 µL of SPB and 50 µL bacterial suspension. 
Sterility control well contained 100 µL BHI broth to test 
and ensure that broth was not contaminated.
The plates were sealed with aluminum foil and were 
incubated at 37 °C for 2 h then 50 µL of the contents of 
the well were pipetted on BHI agar plates and incubated 
for 24  h. The bactericidal activity was expressed as the 
MBC which is the concentration at which 99.9% of the 
colonies are killed and the Lethal dose 50  (LD50) at which 
50% or more bacteria are killed [23–25]. All experiments 
were run in triplicates.
Polymorphonuclear cell isolation and chemotaxis assay
Polymorphonuclear cell isolation
Neutrophils were isolated from cattle using established 
methods and approved by the University of Saskatch-
ewan’s Committee on Animal Care [26]. For each indi-
vidual animal, blood was pooled into 50  mL tubes and 
diluted with an equal volume of PBS then 12.5  mL of 
the diluted blood was layered over 10 mL of Ficoll Paque 
PLUS (Sigma-Aldrich, St. Louis, USA) while taking care 
to preserve the interface between the two liquids. Fol-
lowing centrifugation at 400  g for 30  min at 20  °C with 
the brake turned off, the lymphocyte layer was discarded 
along with Ficoll and plasma. The pellet was washed in 
20  mL PBS with centrifugation at 500  g with low brake 
for 10 min. The supernatant was discarded and the pel-
let was suspended in equal volume of sterile water and 
gently mixed for 20 s followed by addition of equal vol-
ume of 1.8% NaCl to restore tonicity. The mixture was 
centrifuged at 500 g for 10 min and followed by another 
washing and centrifugation at 4 °C. The resulting neutro-
phil pellet was resuspended in PBS. Bovine neutrophils, 
collected in the above manner had more than 92% purity, 
and their viability was greater than 95% based on Trypan 
blue exclusion assay. Therefore, we use the term neutro-
phils in the manuscript.
Chemotaxis assay
We used fMLP (114  nm) as the chemoattractant. 
Approximately 25 μL of peptides (50 μg/mL) was put into 
lower compartment wells of a 48-well Boyden Chamber. 
After the fMLP loading, the polycarbonate membrane fil-
ter (pore size 5 μM), with the shiny side up, was placed 
over the lower chamber. Next, silicone gasket was placed 
on the membrane, then the upper chamber was put on 
top of the gasket and the lug nuts firmly secured. Cell 
suspension (1 ×  106 cells) was then placed over control 
wells and N/P wells (neutrophil at top and peptide in the 
bottom wells). The whole assembly was then incubated 
at 37 °C in humidified air with 5%  CO2 for 20 min. After 
the incubation, the Boyden chamber was disassembled 
and the membrane carefully held with the bulldog clamp 
and the cells on the upper shiny surface scraped with the 
wiper blade. Next, the filter membrane was stained with 
the Diff-Quick and mounted on glass slide with the bot-
tom side up. The cells within the filter pores were then 
counted in five random fields under light microscope at 
40×. The results are presented as the number of migrated 
neutrophils per microscopic field.
Migration inhibition assay
Since peptides can be immunomodulatory, migration 
inhibition was carried out to determine if the peptides 
inhibit neutrophil migration. This assay was performed in 
the same manner as the chemotaxis assay with the only 
difference being that peptide and neutrophils were incu-
bated together on the top of the filter; 25 μL of 100 μg/
mL peptide and 25 μL (2 ×  106 cells) of neutrophils were 
put together. In the lower wells 25 μL of 114 nM fMLP 
(chemoattractant) was placed followed by the staining 
and counting of the cells as described above.
Statistical analysis
Data from susceptibility testing assay was analyzed 
using the non-parametric statistics (using ranked data), 
because the data were variable among groups most likely 
due to small sample size. The comparisons were done 
using contrasts (1 compared to 2, 2 compared to 3, and 
so on), given that we expected a decrease in colony count 
with increasing concentrations. Groups were considered 
statistically significant if the P-value was less than 0.05. 
A One-way ANOVA followed by Dunnets Multiple Com-
parisons test was performed on data obtained from the 
chemotaxis and migration inhibition assay. Significance 
was recorded when P < 0.05. Computer software Graph-
Pad Prism 6 and SPSS (GraphPad Software, San Diego, 




Five peptides, HBD3, 28AA HBD3, 20AA HBD3, 10AA 
HBD3, and Microcin J25 (MccJ25) were evaluated in this 
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study. Because wild type HBD3 is commercially avail-
able, we purchased it at 95% purity (AnaSpec Inc.). The 
amino acid sequences of the HBD3 and its analogues and 
MccJ25 studied are shown in Figure 1.
Approximately 3  mg Wild-type MccJ25 was obtained 
by over expression protocol already established by Soudy 
et  al. [27]. After purification by flex column the crude 
MccJ25 was finally purified with the C-18 RP-HPLC, at 
a flow rate of 2  mL/min 55–80% methanol/water mix-
ture in 55 min. Various fractions at different time points 
were obtained. Fraction containing the desired mass 
for MccJ25 eluted at 20  min on the RP-HPLC column 
(Additional File 1). The calculated mass for MccJ25 was 
2107 MW and the mass was determined to be [M +  H]+ 
2107.7 (Additional File 1). The elute from desired peak 
was collected, pooled and lyophilized. The yield or the 
concentration of MccJ25 was measured using UV–Vis 
spectrophotometer at 278 nm.
SPPS synthesis of HBD3 analogues
Three C-terminal HBD3 analogues were designed as 
short fragments of wtHBD3 with different amino acid 
chain lengths (Figure 1). In each analogue, cysteine was 
replaced with valine to remove di-sulfide linkages and 
render the fragment linear and more stable. Standard 
SPPS with Fmoc chemistry was used for the synthesis of 
the three analogues. Manual SPPS was carried out in a 
reaction vessel starting with the shorter 10AA analogue. 
Amino acid chain was built on 2-chlorotrityl resin in the 
reaction vessel. The proper peptide chain elongation was 
ensured with Ninhydrin test after every coupling step and 
test cleavage after every third amino acid. After building 
10AA amino acid chain, the peptide was cleaved from 
the solid support or resin. A treatment with 95% TFA, 5% 
tri-isopropylsilane in water, for 2 h at room temperature 
with continuous shaking of the vessel was used to simul-
taneously de-protect the side chains and cleave the crude 
peptide from the resin. On a semi-preparative RP-HPLC 
column using gradient elution, 22 mg of the crude 10AA 
analogue was purified. A gradient method with 10–35% 
acetonitrile/water in 60 min with a flow rate of 1.3 mL/
min was used on the RP-HPLC for the purification of 
crude synthetic peptide 10 AA.
Peaks eluted at 10.9–11.2, 13.4–14.5, 17–18, 26–27, 
27–28, and 33–34  min were collected. Mass spec, 
through MALDI-TOF with α-cyano-4-hydroxycinnamic 
acid (HCCA) as a matrix, for all of the elutions was taken 
and elution at peak 13.4–14.5 had the correct mass. Cal-
culated mass for 10AA was 1283 and the mass found was 
[M +  H]+ 1282.6. (Additional file 7).
20AA analogue was synthesized in a manner similar to 
10AA analogue. Beyond the addition of tenth amino acid, 
ninhydrin test and test cleavage were performed after 
every third coupling. Double coupling was performed for 
the last four amino acids, because of the positive ninhy-
drin test after single coupling. The purification scheme 
used for 20AA analogue was the same as the 10AA ana-
logue. Peaks eluted at 13–14.5, 23–25, 29–30, 35–36.5, 
and 51.5–53 min were collected. Similarly, the MALDI-
TOF mass spectrum for all of the elutions was taken and 
the correct mass was found in elution at peak 35–36.5 
(Additional file  3). Calculated mass for 20AA was 2384 
and the mass found was [M +  H]+ 2383.3 (Additional 
file 3). However, complete resolution between 19AA ana-
logue and 20AA analogue could not be achieved. Several 
other HPLC gradient were tried to achieve resolution of 
20AA analogue from other truncated peptides but best 
results were achieved with 10–35% acetonitrile/water in 
60  min with a flow rate of 1.3  mL/min scheme. None-
theless, the major component from the eluate was 20AA 
analogue and 19AA analogue was only a small fraction. 
Overall 24–28 mg of purified peptide was obtained.
The synthesis of 30AA, linear with all cysteines 
mutated with valine, was attempted. However, the chain 
could be elongated only up to 28 AA analogue as iden-
tified by mass spec of crude peptide showing a mass of 
3386.4 [M +  H]+ (Calculated 3387) (Additional file  4). 
The coupling of arginine to the 28th amino acid valine 
Figure 1 Amino acid sequences of HBD3, and the three HBD3 fragments. Substitution of cysteine residues with valine in the fragments is 
shown in red.
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could not be achieved even with three consecutive cou-
plings. Since the manual synthesis of such a long amino 
acid chain is usually fraught with many pitfalls, the elon-
gation of a 28 amino acid chain was a satisfactory result, 
because the appropriate balance of positive charge and 
hydrophobicity was attained.
Microbicidal effect of peptides
Peptides HBD3, its analogues and Mccj25 were assessed 
for Minimum bactericidal concentration (MBC). MBC is 
described as the lowest concentration of each drug that 
resulted in a 99.9% reduction in CFU of the initial inocu-
lum. All the peptides have shown intermediate to potent 
killing activity towards M. haemolytica (Figures 2, 3). The 
final inoculum size should be 5 ×  105 cfu/mL, but varied 
between 1 ×  105 and 1 ×  106 cfu/mL and is acceptable as 
per M7-A7 guidelines. However, some published studies 
have taken final inoculum in the range of  104–105 cfu/mL 
[28].
The comparison of antibacterial activity at different 
concentrations of HBD3 revealed that HBD3 was equally 
active at 100.0 µg/mL and 50.0 µg/mL. However, the con-
centrations 50  µg/mL and 25.0  µg/mL, 25.0  µg/mL and 
12.5 µg/mL, 12.5 µg/mL and 6.3 µg/mL, and 6.3 µg/mL 
and 3.1 µg/mL were statistically different. The concentra-
tions 3.1 µg/mL and 0.8 µg/mL were not active and there 
Figure 2 Comparisons between microbicidal effects of eight different concentrations of HBD3 and HBD analogues. Comparisons were 
performed using contrasts for example 100.0 μg/mL was compared to 50.0 μg/mL, 25.0 μg/mL compared to 12.5 μg/mL employing non-parametric 
statistics (ranked data). Statistical significance between two concentrations is indicated by *P < 0.05 and **< 0.01. The data are represented as 
Mean ± SEM.
Figure 3 Comparisons between microbicidal effects of eight 
different concentrations of MccJ25. Comparisons were performed 
using contrasts for example 100.0 μg/mL was compared to 50.0 μg/
mL, 25.0 μg/mL compared to 12.5 μg/mL employing non-parametric 
statistics (ranked data). Statistical significance between two 
concentrations is indicated by *P < 0.05 and **< 0.01. The data are 
represented as Mean ± SEM.
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was no statistical difference between them (Additional 
file 7 and Figure 2A).
The activity of 10AA at all the concentrations was simi-
lar without any statistical difference. It is worth noting 
that this is observed only with 10AA analogue which is 
very likely due to a smaller inoculum size  (104  cfu/mL) 
used (Additional file 8 and Figure 2B). Similar to HBD3, 
20AA analogue was equally active at both 50.0  µg/mL 
and 100.0 µg/mL. However, the concentrations 50.0 µg/
mL and 25.0  µg/mL, 25.0  µg/mL and 12.5  µg/mL, 
12.5 µg/mL and 6.3 µg/mL, and 6.3 µg/mL and 3.1 µg/mL 
were statistically different from each other. Again, con-
centrations 3.1 µg/mL and 0.8 µg/mL were not active and 
there was no statistical difference among them (Addi-
tional file 9 and Figure 2C).
The antibacterial effect of 28AA analogue’s concentra-
tions 100.0 µg/mL to 6.3 µg/mL was statistically similar 
as was the antibacterial effect for the concentrations 3.1–
0.8  µg/mL. The only difference was observed between 
3.1 and 6.3 µg/mL (Additional file 10 and Figure 2D and 
Additional file  3). Additional file  3 shows a clear dose 
response when M. haemolytica was treated with crude 
28AA analogue. The number of colony forming units 
progressively increased with decreasing peptide concen-
tration. The MBC and  LD50 of all the peptides have been 
compared (Table 1). While HBD3 and HBD3 20AA ana-
logues have equal MBC values of 50 µg/mL, MBC value 
for HBD3 28AA analogue was the lowest at 12.5 µg/mL, 
and MccJ25 had highest MBC value of 100 µg/mL (Addi-
tional file  10). Nearly comparable  LD50 values do not 
effectively discriminate different peptides. However, the 
value of  LD50 is apparent in the fact that it shows MccJ25 
kills half of the bacterial population at 6.3 µg/mL.
MccJ25 exhibited microbicidal effect; however, the 
reduction in colony count was much less in comparison 
to other peptides Different concentrations of MccJ25 
were compared for antibacterial activity against M. 
haemolytica but no statistically significant difference was 
observed (Additional file 11 and Figure 3).
Chemotaxis assay
HBD3 is chemotactic for human neutrophils [29]. The 
chemotaxis of bovine neutrophils in response to HBD3, 
HBD3 20AA analogue, and HBD3 28AA analogue 
at 50.0  μg/mL was studied. Neutrophil migration in 
response to HBD3 and 20AA analogue was found to be 
statistically significant when compared with PBS (Nega-
tive control), but the difference between PBS and 28AA 
was not significant (Figure  4). The result shows that 
HBD3 and HBD3 20AA analogue were chemotactic for 
bovine neutrophils at 50.0  μg/mL where as 28AA ana-
logue was not.
Migration inhibition assay
Bovine neutrophils were treated with 50.0  μg/mL of 
HBD3, HBD3 20AA analogue, and HBD3 28AA ana-
logue and the effect of peptides on neutrophil migra-
tion towards fMLP was studied. Neutrophil migration 
towards fMLP when neutrophils were incubated with 
HBD3, HBD3 20AA analogue, and HBD3 28AA ana-
logues was statistically different from the PBS, which 
shows that none of the peptides inhibited migration of 
neutrophils towards fMLP (Figure 5).
Discussion
To our knowledge, this is the first study to show that 
based on MBC and  LD50 data HBD3 and its analogues 
and MccJ25 peptides kill M. haemolytica in vitro. In addi-
tion, the peptides are chemotactic for the bovine neutro-
phils. These data are important considering the economic 
impact of morbidity and mortality associated with BRD 
Table 1 Comparisons of MBC and LD50 of the peptides 
MBC (Minimum Bactericidal Concentration) is the concentration of antibiotic 
at which 99.9% of the CFU in the final inoculum are killed and  LD50 is the lethal 
dose for ≥ 50% of bacteria.
Peptide MBC (μg/mL) LD50 (μg/mL)
HBD3 10AA analogue 6.3 ≥ 3.1
HBD3 20AA analogue 50.0 3.1
HBD3 28AA analogue 12.5 3.1
HBD3 50.0 6.3
MccJ25 > 100.0 6.3
Figure 4 Chemotaxis assay of the peptides against bovine 
neutrophils. Number of neutrophils that migrated in response to 
HBD3, HBD3 20AA analogue and, HBD3 28AA analogue after 20 min 
incubation at 37 °C. The three peptides were used at a concentration 
of 50.0 μg/mL. fMLP is the positive control. Mean ± SEM of three 
independent experiments. One way ANOVA was followed by 
Dunnett’s multiple comparison test (P ≤ 0.0036). Asterisks show 
significant difference from PBS (Negative control) *P < 0.05.
Page 7 of 11Dhingra et al. Vet Res           (2021) 52:83  
caused by M. hemotlyica. The development and use of 
antimicrobial peptides may also provide us with tools to 
reduce the use of antibiotics and thus reduce the threat of 
anti-microbial resistance and their residues in meat.
HBD3 and MccJ25 were selected as potential candi-
dates. Wild-type HBD3 with purity ≥ 95% was com-
mercially obtained, whereas MccJ25 was expressed in E. 
coli followed by purification and characterization. The 
data contained in this study show synthesis and charac-
terization of three analogues of HBD3. We successfully 
synthesized HBD3 analogues (Figure  1) namely 10AA, 
20AA but couldn’t synthesize 30AA using Fmoc-SPPS. 
During SPPS, the -amino acid chain could be elongated 
up to only 28AA as confirmed by MALDI-TOF even after 
repeated coupling. Mass spectrometry of 28AA crude 
peptide shows other peaks along with 28AA analogue 
peak suggesting impurities in the crude peptide. The 
crude peptides (MccJ25, 10AA and 20AA analogue) were 
purified by RP-HPLC and then by MALDI-TOF mass 
spectrometry to confirm mass of the crude and pure 
peptides.
In vitro susceptibility tests for cationic peptides are 
challenging to perform because polycationic peptides 
tend to precipitate and bind to the anionic surface of 
bacterial cells and plastic surface. There are data on the 
comparison of two methods for evaluating the in  vitro 
antimicrobial activities of cationic AMP’s [30]. The com-
parative data showed that NCCLS protocol gave MICs 
and MBCs values that were four times higher than the 
method proposed by Hancock [30]. We used the 96-well 
plates for antimicrobial evaluation to reduce the possi-
bility of false higher MBCs and MICs as apparent in the 
results of Giacometti and the results of our preliminary 
MIC experiment (data not shown). However, we used 
the NCCLS definition of MBC which is the lowest con-
centration of each drug that resulted in a 99.9% reduc-
tion in CFU of the initial inoculum whereas the Hancock 
method defines the MBC as the lowest concentration of 
each drug that prevented any residual colony formation. 
In addition to the MBC, we also carried out the MIC 
assays. This classification of peptide potency however is 
arbitrary, “a strain was defined as sensitive to the peptide 
if MBC levels were < 10 μg/mL, as intermediately sensi-
tive if MBC levels were 10–100 μg/mL, or as resistant at 
MBC levels of > 100 μg/mL” [28].
In our study, HBD3 was highly effective in killing M. 
haemolytica with MBC value of 50 μg/mL. The testing of 
the bactericidal activity of the HBD3 against 28 species 
and 55 strains of Gram-positive cocci and Gram-negative 
fermentative and non-fermentative rods showed it be 
intermediately or highly effective [28]. However, MBC 
value in our study is higher when compared to the data 
from Sahly et  al. in which only three strains out of 55 
tested showed intermediate susceptibility (MBC value of 
50.0 μg/mL), whereas rest of the strains were highly sen-
sitive to HBD3 with MBC’s ranging from 0.1 to 6.3  μg/
mL [28]. The reason for lower MBC’s in their study could 
be attributed to use of a lower final bacterial inoculum 
of  104 to  105/mL [28] compared  105 to  106/mL used in 
our study. This phenomenon of lower MBC correspond-
ing with low final inoculum size was also observed in 
our data from 10AA analogue. We tested various con-
centrations of this analogue with final inoculum size of 
 104 cells/mL of M. haemolytica and this gave us MBC of 
6.3 μg/mL.
HBD3 analogues showed intermediate activity against 
M. hemolytica. 20AA analogue was active against M. 
haemolytica in the same concentration as the wild type 
HBD3, after averaging results from three different experi-
ments, in duplicates, they showed equivalent MBC 
values. 20 AA analogue’s potent activity is likely attribut-
able to its high positive charge (+9). HBD has a higher 
positive charge of +11 but showed anti-microbial activ-
ity similar to that of 20AA analogue. Therefore, it will 
be interesting to replace a couple of positively charged 
basic polar amino acids such as arginine or lysine with 
valine, a neutral nonpolar amino acid, to the analogue 
more hydrophobic and increasingly selective for bacterial 
membranes. This argument is further supported by the 
fact that 10 AA analogue with +7 charge displayed excel-
lent activity against M. haemolytica with 6.3 μg/mL MBC 
Figure 5 Effect of peptides on neutrophil migration towards 
fMLP. Number of neutrophils that migrated towards fMLP (114 nM) 
after 20 min incubation at 37 °C. Neutrophils were treated with 
50.0 μg/mL HBD3, HBD3 20AA analogue and, HBD3 28AA analogue. 
pn/f stands for peptide and neutrophils together in the upper 
well and fmlp in the bottom during 20 min incubation. fMLP is the 
positive control. Mean ± SEM of three independent experiments. One 
way ANOVA was followed by Dunnett’s multiple comparison test 
(P ≤ 0.0036). Asterisks show significant difference from PBS (Negative 
control) *P < 0.05.
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when used with a small inoculum. The testing of this ana-
logue with a higher bacterial inoculum, similar to other 
peptides, would have further bolstered our results. Nev-
ertheless, MBC of 10AA analogue was lower than both 
HBD3 and 20AA analogue and therefore we may be able 
extrapolate this result for higher inoculum size.
Zhou et  al. made eight C-terminal 10AA analogues of 
HBD3 replacing cysteines with either Valine, Tryptophan 
or Tyrosine. Out of these, Valine was easier to build via 
SPPS synthesis and was found to be most active and it 
also didn’t affect antimicrobial activity against bacteria 
such as Pseudomonas aeruginosa [31]. Because cysteine 
and methionine are prone to oxidation, they are often 
replaced by hydrophobic residues such as valine [32]. 
They also made a dimer of Valine 10AA analogue, which 
turned out to be the most potent analogue. Instead of 
making a dimer of 10AA analogue, we chose to elongate 
the peptide chain up to 20 and 28 AA with mutation of all 
Cysteines with Valines. Both 20AA and 28AA analogues 
were active with 28AA peptide showing better activ-
ity than wild-type HBD3 [31]. These researchers further 
tested their peptides against Pseudomonas aeruginosa, 
a Gram −ve bacteria, in the same concentration range 
as ours. Comparing their study with ours, we found that 
the 10AA analogue had similar MBC values (50.0 μg/mL) 
for both Pseudomonas aeruginosa and M. haemolytica. 
However, their dimer was more potent than our 20AA 
analogue. The in  vitro data also shows that removal of 
disulfide bonds does not affect the antimicrobial potency 
of the peptides as shown previously [29]. However, in vivo 
studies are required to further establish this observation.
Studies have shown that some C-terminal (R36-K45) 
analogues of HBD-3 can non-covalently dimerize to 
acquire a defined structure in conditions mimicking 
biological systems or on the lipid bilayer [31, 33]. Eluci-
dating the underlying physico-chemical properties was 
beyond the scope of this study. However, we can speculate 
about the 3D structure of 20AA analogue based on the 
nearly comparable MBC results of 20AA analogue with 
wtHBD3, and findings of the previous studies performed 
with NMR, fluorescence correlation spectroscopy and 
molecular dynamics simulation techniques [33]. It is pos-
sible that the 20AA analogue, dimerized both in aqueous 
solution and on the membrane surfaces, which tend to 
localize the positive charge density which may account for 
its bactericidal efficacy. Alternatively, the 20AA analogue 
would just remain as a linear monomer and its potent 
activity results from increased flexibility due to a loss of 
secondary structure. It also is possible that the activity of 
20AA analogue could be due to truncated peptide (19AA) 
that coeluted during purification of the peptide and was 
used.
MccJ25 kills bacteria by inhibiting the RNA Poly-
merase (RNAP) but this microcin peptide has to enter 
the bacterial cell to accomplish this action. The MccJ5 
sensitive strains have the transporter proteins such as 
outer-membrane protein FhuA and the inner membrane 
protein SbmA to facilitate the transport of the antimicro-
bial peptides into the cells [34, 35]. There are some data 
on the characterization of outer membrane proteins of M. 
haemolytica [36, 37] but we don’t know whether specific 
membrane proteins exist to facilitate transport of MccJ25. 
Furthermore, MccJ25 is not effective against many bacte-
ria of the family Enterobacteriaceae that are not related to 
the MccJ25 producing members [38]. It could be argued 
that MccJ25 shows a narrow action spectrum activity 
in vitro but could be active in vivo against resistant spe-
cies [38, 39]. It has been shown that resistant bacteria 
become susceptible to antibiotics upon their entry into 
the low pH environment in the phagolysosomes of mac-
rophages likely due to the nonspecific MccJ25 uptake into 
the bacterial cell through altered bacterial membrane 
permeability. Also, MccJ25 has been shown to cause dis-
ruption of the membrane potential [39] and hence it can 
be speculated that inside a macrophage M. haemolytica 
could become sensitive to MccJ25.
None of the five peptides tested by us inhibited visible 
growth of the M. haemolytica when compared with the 
positive control. The bactericidal nature of the cationic 
peptides could be the possible explanation of these results. 
Ampicillin at a concentration of 24 μg/mL served as nega-
tive control in our experiments and there was no growth 
in the negative wells. Since there were 10 000–25 000 bac-
teria/well and even if 0.1% of them survived and the pep-
tide got consumed or deactivated over next few hours and 
media was still available for their growth. It is very likely 
that bacteria resumed growth to give false negatives. To 
ascertain the real cause, we need to do additional time-
kill studies as well as testing against other serotypes of M. 
haemolytica.
Anti-microbial peptides kill microbes and have immu-
nomodulatory functions such as modulating recruit-
ment of neutrophils [40]. Defensins such as HBD2 but 
not HBD1 have been shown to be chemotactic for human 
neutrophils pre-treated with TNF-α but not normal 
in vitro [35]. Our data show HBD3 and its 20AA analogue 
to be chemotactic to control untreated bovine neutro-
phils. The difference in results from our experiments and 
those obtained previously may be reflective of species dif-
ferences. Furthermore, we used the peptides at 50.0  μg/
mL and compared to concentrations of 0–10  μg/mL in 
previous studies [41]. To elucidate the chemotactic behav-
ior of 20AA analogue it must be tested against a wide 
concentration range and also for neutrophils from other 
species. It was earlier reported that cysteine mutated 
Page 9 of 11Dhingra et al. Vet Res           (2021) 52:83  
analogues of HBD3 might lose their chemotactic activity. 
It might be possible that bovine neutrophils are generally 
responsive to the Cysteine mutated HBD3 analogues. The 
data by Taylor et al. demonstrated the indispensability of 
three cysteine disulfide bridges for chemotactic activity 
[42]. They showed that HBD3 analogues lacking disulfide 
bridges retained chemoattractant capability. HBD3 ana-
logue which had cysteines replaced with alanines was 
devoid of any chemotactic activity. However, the chemo-
tactic activity was not lost when the fifth cysteine was 
retained and other five were replaced. These anomalous 
results could be due to variation in environmental condi-
tions or different cell species used [42]. The chemotaxis 
in 28AA analogue well and PBS well was statistically not 
different. This anomaly can be accounted for if we take 
into consideration that 28AA was in crude form and had 
contained a few truncated peptides. Lastly, the treatment 
of neutrophils with any of peptides did not affect their 
migration towards fMLP. Nevertheless, there is a need 
for additional experiments to understand the relationship 
between structure and function of the HBD3 and its lin-
ear analogues with their chemotactic property.
Taken together, we report the engineering and synthesis 
of HBD analogues and MccJ25 and report their efficacy 
in killing of M. haemolytica and chemotactic proper-
ties against bovine neutrophils. Further experiments are 
needed to evaluate the activity against other serotypes of 
M. haemolytica, in vivo studies and cell cytotoxicity assays.
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